Table 1.
Promoter methylation status, expression levels, and localizations of Secreted Frizzled Related Protein 1 (SFRP1), beta-catenin, lymphoid-enhancer factor 1 (LEF1), and T-cell factor 1 (TCF1) proteins in astrocytoma samples, and demographic and clinical data of astrocytoma patients
| WorldHealth Organization grade | No. of patients | SFRP1 promoter methylation status* | Levels of expression† |
Sex | Age | Intracranial localization‡ | |||
|---|---|---|---|---|---|---|---|---|---|
| SFRP1 | beta-catenin | LEF1 | TCF1 | ||||||
| AII (diffuse astrocytoma) | 1 | U | 3 | 1 | M | 56 | temporal R | ||
| 2 | U | 3 | 3 | M | 48 | frontal R | |||
| 3 | U | 3 | 3 | F | 38 | occipital R | |||
| 4 | U | 1 | 2 | 2 | 1 | M | 49 | frontal R | |
| 5 | U | 1 | 1 | 2 | 1 | M | 44 | insular L | |
| 6 |
U |
1 |
2 |
1 |
2 |
M |
32 |
temporal L |
|
| AIII (anaplastic astrocytoma) | 1 | U | 2 | 2 | F | 55 | frontal L | ||
| 2 | U | 3 | 3 | M | 58 | frontal R | |||
| 3 | U | 3 | 3 | M | 46 | frontal L | |||
| 4 | U | 1 | 2 | 2 | 1 | F | 34 | frontoparietal parasagittal R | |
| 5 | U | 1 | 2 | 3 | 3 | M | 24 | frontal L | |
| 6 |
M/U |
2 |
2 |
2 |
1 |
M |
51 |
frontal parasagittal L |
|
| G IV (glioblastoma) | 1 | U | 1 | 1 | 3 | 2 | M | 68 | parietal R |
| 2 | U | 1 | 3 | 2 | 1 | M | 56 | frontal R | |
| 3 | M/U | 1 | 2 | 1 | F | 54 | temporooccipital R | ||
| 4 | M/U | 2 | 2 | F | 62 | parietal R | |||
| 5 | M/U | 1 | F | 58 | temporoparietal L | ||||
| 6 | U | 1 | 1 | 3 | 2 | F | 77 | temporal L | |
| 7 | U | 1 | 1 | 3 | 3 | M | 60 | temporal L | |
| 8 | M/U | 1 | 3 | 3 | 1 | F | 56 | parietal L | |
| 9§ | U | 2 | 2 | 3 | 3 | M | 31 | temporal L | |
| 10 | U | 3 | 3 | 1 | 1 | F | 71 | frontal L | |
| 11 | M/U | 3 | 1 | F | 74 | frontal R | |||
| 12 | M/U | 1 | 2 | 3 | 3 | F | 56 | temporal R | |
| 13II | M/U | 2 | 1 | 3 | 3 | M | 38 | temporooccipital R | |
| 14II | 2 | 1 | 3 | 3 | M | 54 | frontal R | ||
*M – methylated; U – unmethylated; bold – pronouncedly present, regular – present.
†1 – weak or lack of expression; 2 – moderate expression; 3 – strong expression.
‡R – right; L– left.
§Patients with isocitrate dehydrogenase 1 mutation.
IIPatients with ATRX Chromatin Remodeler mutations.